SOURCE: London & Pacific Healthcare, Inc.

August 08, 2008 13:39 ET

Healthcare Specialist Launches Orthobiologic Company

EL SEGUNDO, CA--(Marketwire - August 8, 2008) - London & Pacific Healthcare, Inc. (PINKSHEETS: LDPH) and (FRANKFURT: EGU) ("London & Pacific," the "Company"), the healthcare development specialist company, announced the formation of The Orthobiologic Institute, LLC ("TOBI") by London & Pacific Healthcare Ventures, LLC, a subsidiary of the Company.

TOBI will specialize in the development and management of specialty centers providing autologous transplantation of tissue (platelet rich plasma, stem cells) to address musculoskeletal diseases and conditions. These forms of treatment serve as alternatives and adjuncts to orthopaedic surgery. TOBI, the first such company of its kind, will work closely with existing high-end orthopedic practices and ambulatory surgical centers to roll out its strategy into this fast-growing market.

The size of the orthobiologic market focused on the knee and hip alone exceeds $1 billion annually and is growing at the rate of 20% per year. The CEO of TOBI is Dr. Michael S. Sinel and its Medical Director is Dr. Steven E. Sampson.

With offices in Los Angeles, London and Mumbai, London & Pacific Healthcare, Inc. is a specialist in the development and management of healthcare companies and organizations, worldwide. The Company website:

Safe Harbor Disclaimer: This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this release that are "forward-looking statements" are based on current expectations and assumptions that are subject to known and unknown risks, uncertainties or other factors which may cause actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Actual results could differ materially because of factors such as: the effect of general economic and market conditions, entry into markets with vigorous competition, market acceptance of new products and services, continued acceptance of existing products and services, technological shifts, and delays in product development and related product release schedules, any of which may cause revenues and income to fall short of anticipated levels.

Contact Information